Skip to content
LGBTQIA, Medical Health Aged Care

Dash Heath-Paynter confirmed as Health Equity Matters CEO

Health Equity Matter 2 mins read

Health Equity Matters, Australia’s HIV and LGBTIQA+ health federation, is pleased to announce the appointment of Dash Heath-Paynter as its new chief executive officer.

 

Dash takes on the leadership of Health Equity Matters after serving almost eight years as deputy CEO. During that period, Dash oversaw policy development, political advocacy and engagement. This encompassed the national community response to Mpox, including co-chairing the National Mpox Taskforce.

 

“We are delighted to confirm the appointment of Dash Heath-Paynter as our new chief executive,” Health Equity Matters President, Mark Orr AM, said. “Dash brings deep, sustained experience in HIV and LGBTIQA+ health advocacy and policy. Dash’s skills and experience will serve our communities well as we push for the virtual elimination of HIV transmission and a more robust community-led response to the health needs of LGBTIQA+ communities.”

 

Dash is a member of the Medical Services Advisory Committee (MSAC) PICO Advisory Sub-Committee (PASC); the Therapeutics Goods Administration (TGA) Advertising Consultative Committee, the National HIV PrEP Guidelines Committee and the National HIV Testing Policy Expert Reference Committee. 

 

“It is a profound honour and privilege to take on the executive leadership of the Health Equity Matters at this pivotal moment,” Dash Heath-Paynter said. “My predecessor, Adjunct Professor Darryl O’Donnell established strong foundations for us to make monumental progress towards better health responses for LGBTIQA+ people, the virtual elimination of HIV transmission and continuing support for people living with HIV. 

 

“We have an incredibly talented and motivated team at Health Equity Matters and we take seriously our role in protecting and promoting the partnership of researchers, clinicians, community and government that is at the centre of Australia’s HIV response.

 

“I look forward to working closely with the Federal Government to drive further progress for the communities we represent and serve.”

 

Prior to joining Health Equity Matters’ Dash worked as a senior policy analyst at Health Equity Matters’ Victorian member organisation, the Victorian AIDS Council, now Thorne Harbour Health.

 

Dash is an Adjunct Senior Lecturer at the Kirby Institute, at the University of New South Wales and holds degrees in law and arts. He is a graduate of the Harvard University Kennedy School of Government Executive Leadership Program.

 

Interview requests: Nick Lucchinelli 0422229032

 

More from this category

  • Medical Health Aged Care
  • 31/10/2024
  • 17:55
Kyowa Kirin Co., Ltd.

Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company

Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to further deliver on company’s 2030…

  • Contains:
  • Medical Health Aged Care
  • 31/10/2024
  • 12:10
MannKind

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its first site for its Phase 3 clinical trial evaluating efficacy and safety of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The study,…

  • Business Company News, Medical Health Aged Care
  • 31/10/2024
  • 11:03
Firebrick Pharma

Agreement Signed to Market Nasodine to Healthcare Professionals in Singapore

Firebrick Pharmais pleased to announce that it has executed a Marketing Representation Agreement (the “Agreement”) with Singapore-based, Innorini, trading as Innorini Life Sciences (“Innorini”). The initial term of the Agreement is one year with the option to renew for subsequent one-year terms by mutual agreement. Under the Agreement, Innorini will undertake “Marketing Services” commencing 1 November 2024. The Marketing Services comprise sampling and promotion of Nasodine® Nasal Spray (“Nasodine”) to General Practitioners (“GPs”) and hospital-based doctors and pharmacists (collectively “HCPs”) in Singapore. In addition to building awareness and support of Nasodine by HCPs, Innorini will be expected to sell Nasodine…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.